Trial Profile
Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Bimatoprost/timolol (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions
- Sponsors Allergan
- 12 Nov 2022 Results published in the Ophthalmology and Therapy
- 03 Jul 2018 Status changed from active, no longer recruiting to completed.
- 24 Jan 2018 Planned End Date changed from 15 Mar 2018 to 29 Jun 2018.